These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36974751)

  • 1. SWAP70 Overexpression Protects Against Pathological Cardiac Hypertrophy in a TAK1-Dependent Manner.
    Qian Q; Hu F; Yu W; Leng D; Li Y; Shi H; Deng D; Ding K; Liang C; Liu J
    J Am Heart Assoc; 2023 Apr; 12(7):e028628. PubMed ID: 36974751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TMEM100 acts as a TAK1 receptor that prevents pathological cardiac hypertrophy progression.
    Zhang BB; Zhao YL; Lu YY; Shen JH; Li HY; Zhang HX; Yu XY; Zhang WC; Li G; Han ZY; Guo S; Zhang XT
    Cell Commun Signal; 2024 Sep; 22(1):438. PubMed ID: 39261825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1.
    Zhao J; Jiang X; Liu J; Ye P; Jiang L; Chen M; Xia J
    J Am Heart Assoc; 2021 Feb; 10(4):e014311. PubMed ID: 33522247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GCN5-mediated regulation of pathological cardiac hypertrophy via activation of the TAK1-JNK/p38 signaling pathway.
    Li J; Yan C; Wang Y; Chen C; Yu H; Liu D; Huang K; Han Y
    Cell Death Dis; 2022 Apr; 13(4):421. PubMed ID: 35490166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ubiquitin-specific protease 19 blunts pathological cardiac hypertrophy via inhibition of the TAK1-dependent pathway.
    Miao R; Lu Y; He X; Liu X; Chen Z; Wang J
    J Cell Mol Med; 2020 Sep; 24(18):10946-10957. PubMed ID: 32798288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switch-associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1.
    Qian Q; Li Y; Fu J; Leng D; Dong Z; Shi J; Shi H; Cao D; Cheng X; Hu Y; Luo Q; Hu M; Ran Y; Tang H; Liu H; Liu J
    Hepatology; 2022 Jun; 75(6):1507-1522. PubMed ID: 34689362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FBXW5 acts as a negative regulator of pathological cardiac hypertrophy by decreasing the TAK1 signaling to pro-hypertrophic members of the MAPK signaling pathway.
    Hui X; Hu F; Liu J; Li C; Yang Y; Shu S; Liu P; Wang F; Li S
    J Mol Cell Cardiol; 2021 Feb; 151():31-43. PubMed ID: 32971071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tripartite Motif 8 Contributes to Pathological Cardiac Hypertrophy Through Enhancing Transforming Growth Factor β-Activated Kinase 1-Dependent Signaling Pathways.
    Chen L; Huang J; Ji YX; Mei F; Wang PX; Deng KQ; Jiang X; Ma G; Li H
    Hypertension; 2017 Feb; 69(2):249-258. PubMed ID: 27956576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The C-terminus of the long AKAP13 isoform (AKAP-Lbc) is critical for development of compensatory cardiac hypertrophy.
    Taglieri DM; Johnson KR; Burmeister BT; Monasky MM; Spindler MJ; DeSantiago J; Banach K; Conklin BR; Carnegie GK
    J Mol Cell Cardiol; 2014 Jan; 66():27-40. PubMed ID: 24161911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HINT1 (Histidine Triad Nucleotide-Binding Protein 1) Attenuates Cardiac Hypertrophy Via Suppressing HOXA5 (Homeobox A5) Expression.
    Zhang Y; Da Q; Cao S; Yan K; Shi Z; Miao Q; Li C; Hu L; Sun S; Wu W; Wu L; Chen F; Wang L; Gao Y; Huang Z; Shao Y; Chen H; Wei Y; Chen F; Han Y; Xie L; Ji Y
    Circulation; 2021 Aug; 144(8):638-654. PubMed ID: 34098726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TBC1D25 Regulates Cardiac Remodeling Through TAK1 Signaling Pathway.
    Guo S; Liu Y; Gao L; Xiao F; Shen J; Xing S; Yang F; Zhang W; Shi Q; Li Y; Zhao L
    Int J Biol Sci; 2020; 16(8):1335-1348. PubMed ID: 32210723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNF207 exacerbates pathological cardiac hypertrophy via post-translational modification of TAB1.
    Yuan L; Bu S; Du M; Wang Y; Ju C; Huang D; Xu W; Tan X; Liang M; Deng S; Yang L; Huang K
    Cardiovasc Res; 2023 Mar; 119(1):183-194. PubMed ID: 35352799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gramine protects against pressure overload-induced pathological cardiac hypertrophy through Runx1-TGFBR1 signaling.
    Xu L; Su Y; Yang X; Bai X; Wang Y; Zhuo C; Meng Z
    Phytomedicine; 2023 Jun; 114():154779. PubMed ID: 37023527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STEAP3 (Six-Transmembrane Epithelial Antigen of Prostate 3) Inhibits Pathological Cardiac Hypertrophy.
    Li PL; Liu H; Chen GP; Li L; Shi HJ; Nie HY; Liu Z; Hu YF; Yang J; Zhang P; Zhang XJ; She ZG; Li H; Huang Z; Zhu L
    Hypertension; 2020 Oct; 76(4):1219-1230. PubMed ID: 32862709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C1q-tumour necrosis factor-related protein-3 exacerbates cardiac hypertrophy in mice.
    Ma ZG; Yuan YP; Zhang X; Xu SC; Kong CY; Song P; Li N; Tang QZ
    Cardiovasc Res; 2019 May; 115(6):1067-1077. PubMed ID: 30407523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C1q-TNF-related protein-3 attenuates pressure overload-induced cardiac hypertrophy by suppressing the p38/CREB pathway and p38-induced ER stress.
    Zhang B; Zhang P; Tan Y; Feng P; Zhang Z; Liang H; Duan W; Jin Z; Wang X; Liu J; Gao E; Yu S; Yi D; Sun Y; Yi W
    Cell Death Dis; 2019 Jul; 10(7):520. PubMed ID: 31285424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-specificity phosphatase 14 protects the heart from aortic banding-induced cardiac hypertrophy and dysfunction through inactivation of TAK1-P38MAPK/-JNK1/2 signaling pathway.
    Li CY; Zhou Q; Yang LC; Chen YH; Hou JW; Guo K; Wang YP; Li YG
    Basic Res Cardiol; 2016 Mar; 111(2):19. PubMed ID: 26891723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway.
    Liao HH; Zhang N; Meng YY; Feng H; Yang JJ; Li WJ; Chen S; Wu HM; Deng W; Tang QZ
    Oxid Med Cell Longev; 2019; 2019():6304058. PubMed ID: 31885808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caspase recruitment domain 6 protects against cardiac hypertrophy in response to pressure overload.
    Li L; Chen W; Zhu Y; Wang X; Jiang DS; Huang F; Wang L; Xiang F; Qin W; Wang Q; Zhang R; Zhu X; Li H; Chen X
    Hypertension; 2014 Jul; 64(1):94-102. PubMed ID: 24777975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Transmembrane BAX Inhibitor Motif Containing 1 Alleviates Pathological Cardiac Hypertrophy.
    Deng KQ; Zhao GN; Wang Z; Fang J; Jiang Z; Gong J; Yan FJ; Zhu XY; Zhang P; She ZG; Li H
    Circulation; 2018 Apr; 137(14):1486-1504. PubMed ID: 29229612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.